COHERUS BIOSCIENCES I

Coherus BioSciences Management to Present at H.C. Wainwright 24th Annual Global Investment Conference

12 Sep 2022 08:30:00 By Nasdaq GlobeNewswire

Coherus BioSciences Announces New Employment Inducement Grants

29 Aug 2022 20:49:11 By Nasdaq GlobeNewswire

Coherus BioSciences Reports Second Quarter 2022 Results and Provides Business Update

04 Aug 2022 16:01:01 By Nasdaq GlobeNewswire

FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability Exclusivity

02 Aug 2022 19:15:15 By Nasdaq GlobeNewswire

Coherus BioSciences Announces New Employment Inducement Grants

01 Aug 2022 23:15:00 By Nasdaq GlobeNewswire

Coherus BioSciences to Report Second Quarter 2022 Financial Results on August 4th, 2022

28 Jul 2022 16:01:00 By Nasdaq GlobeNewswire

Coherus and Junshi Biosciences Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma

06 Jul 2022 08:00:01 By Nasdaq GlobeNewswire

Coherus BioSciences Announces New Employment Inducement Grants

22 Jun 2022 16:30:00 By Nasdaq GlobeNewswire

Coherus BioSciences Appoints Dr. Jill O’Donnell-Tormey to its Board of Directors

11 May 2022 18:00:00 By Nasdaq GlobeNewswire

Coherus BioSciences Management to Present at Upcoming Investor Conferences

10 May 2022 08:45:00 By Nasdaq GlobeNewswire

Coherus BioSciences Reports First Quarter 2022 Results

05 May 2022 16:01:01 By Nasdaq GlobeNewswire

Coherus BioSciences Appoints Charlie Newton to Board of Directors

05 May 2022 08:31:00 By Nasdaq GlobeNewswire

Coherus BioSciences Announces New Employment Inducement Grants

03 May 2022 21:44:59 By Nasdaq GlobeNewswire

Coherus and Junshi Biosciences Receive Complete Response Letter from U.S. FDA for Toripalimab BLA

02 May 2022 07:00:01 By Nasdaq GlobeNewswire

CORRECTION - Coherus BioSciences to Report First Quarter 2022 Financial Results on May 5th, 2022

29 Apr 2022 16:01:00 By Nasdaq GlobeNewswire

Coherus BioSciences to Report First Quarter 2022 Financial Results on May 5th, 2022

29 Apr 2022 08:45:00 By Nasdaq GlobeNewswire

Coherus and Junshi Biosciences Announce PD-1 Inhibitor Toripalimab Granted Orphan Drug Designation for Small Cell Lung Cancer in the United States

14 Apr 2022 08:30:00 By Nasdaq GlobeNewswire

Coherus and Junshi Biosciences Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting

08 Apr 2022 13:10:45 By Nasdaq GlobeNewswire

Coherus BioSciences Announces New Employment Inducement Grants

05 Apr 2022 16:30:00 By Nasdaq GlobeNewswire

Coherus Highlights Anticipated New Product Launches and Immuno-oncology Growth Strategy at Analyst Day Event

29 Mar 2022 09:15:00 By Nasdaq GlobeNewswire